Book previews

Saturday, January 31, 2015

Breaking News From Atlanta!

cartoon, cartoons, hhv-6, aids, gallo, fraud, ruscetti, hiv, cfs, fauci, causation, transmission

Increase Your Natural Killer Cells: Buy This Book!

 

The effect of mirthful laughter on stress and natural killer cell activity.

 http://www.ncbi.nlm.nih.gov/pubmed/12652882

CONCLUSION:

Laughter may reduce stress and improve NK cell activity. As low NK cell activity is linked to decreased disease resistance and increased morbidity in persons with cancer and HIV disease, laughter may be a useful cognitive-behavioral intervention.


Julian Lake's The Chronic Fatigue Syndrome Follies: Cartoons about an epidemic of lies. Now in print or on Kindle and free on Kindle Unlimited.



The title of this collection of cartoons by Julian Lake was inspired by the The March of Folly, a stunning work by the late Barbara Tuchman. To try and explain why certain political disasters in history have occurred, Tuchman uses the very apt construct of "folly," which she defines as the "pursuit of policy contrary to the self-interest of the constituency or state involved." Tuchman analyzes four periods in history that are characterized by enormous folly. Julian Lake's collection is in many ways about a fifth example of such a phenomenon. Surely the last two decades in which so-called "Chronic Fatigue Syndrome" has been called "mysterious" over and over in a cult-like manner (and in the manner of the Big Lie) qualifies as another period of egregious folly. Anyone who has read the lucid journalism of Neenyah Ostrom and Hillary Johnson on "Chronic Fatigue Syndrome" knows precisely what this is  alluding to. And if you don't know, you should find out, lest you be caught aiding and abetting this great folly. That an epidemic as serious as "Chronic Fatigue Syndrome," and so obviously connected to the AIDS epidemic, could be treated to this very day as a "mystery" by the government, by researchers, by the media, and even by most of the patients, has not reduced Julian Lake to tears, for like most humorists, this great tragedy--and folly--is at times, downright funny. Morbid maybe, perhaps dark, and maybe of the gallows school of comedy, but still funny. Julian Lake has tried to capture the folly of two decades of an obvious Chronic Fatigue Syndrome coverup in a manner that is surprisingly three-dimensional, given his hostility to the medical establishment that has been playing deadly political games with CFS. While trying to use humor to capture the horrific plight of CFS patients, in Julian Lake’s democratically mischievous world view, some of the CFS patients have themselves become little emperors without you-know-what. In this collection of cartoons, Julian Lake has given us a rich universe of CFS folly. Unless your easily offended and suffer from CFS political correctness (a new CFS symptom?), don't be afraid to enter Julian Lake’s zany world and have a few laughs. After all, laughter boosts your immune system. And maybe from a political viewpoint, the best antidote to folly is humor.

Friday, January 30, 2015

The Official HHV-6 University Video

A Natural Treatment also for HHV-6? Chronic Fatigue Syndrome? Autism? AIDS?

Report: Washington Metro Ads Feature Fibromyalgia; CBCD Recommends Two Remedies against Latent HSV Linked to FM

The Washington MetroArea Transit Authority is focusing on people with health problems and disabilities that may not be visible to others. (1)
 ROCHESTER, NEW YORK, UNITED STATES, January 29, 2015 /EINPresswire.com/ --

“Infected with the herpes virus (HSV-1 or HSV-2)? The Center for the Biology of Chronic Disease (CBCD), which tested the formula of Novirin and Gene-Eden-VIR in two post-marketing clinical studies, recommends taking these natural antiviral supplements.” – Greg Bennett, CBCD
http://www.virtual-strategy.com/2014/05/21/study-found-link-between-shingles-and-chronic-fatigue-syndrome-cfs-polydna-recommends-gen#axzz3QJCihgy2

Sunday, January 25, 2015

Breaking News from Atlanta

cartoon, cartoons, julian lake, cfs, hhv-6, fraud, cdc, centers for disease control, epidemiology

Are Autism, Chronic Fatigue Syndrome and AIDS all part of a specturm caused by the same agent?
























Are Autism, Chronic Fatigue Syndrome and AIDS all part of a spectrum caused by the same agent?
Are Autism, CFS and AIDS all intertwined subsets of the HHV-6 pandemic that is causing Natural Killer Cell Dysfunction?

Read Plague, now available on Amazon

Plague: One Scientist’s Intrepid Search for the Truth about Human Retroviruses and Chronic Fatigue Syndrome (ME/CFS), Autism, and Other Diseases 

By Kent Heckenlively and Judy Mikovits

Foreword by Hillary Johnson




Time to get serious . . .

cfs, hhv-6, nih, fauci, cover-up, julian lake, aids, autism, ms, cartoon, hhv-6 cartoon

Saturday, January 24, 2015

About HHV-6 University


Welcome to HHV-6 University, a cutting-edge institution of learning devoted to raising international awareness about the very neglected destructive virus that is causing a spectrum of multisystemic illness that includes AIDS, Chronic Fatigue Syndrome, Autism, Multiple Sclerosis, as well all kinds of cancer and digestive disorders. And that's just the tip of the HHV-6 iceberg. Here you'll also learn about the extremely important endogenous retrovirus that HHV-6 induces, one that acts as a superantigen capable of seriously disrupting the immune system. HHV-6 = 50 Shades of AIDS

Here are the books we suggest you purchase to prepare for your classes here.

The Chronic Fatigue Syndrome Follies: Cartoons about an epidemic of lies. [Kindle Edition available on Kindle Unlimited]

America's Biggest Cover-Up: 50 More Things Everyone Should Know About the Chronic Fatigue Syndrome Epidemic And Its Link to AIDS by Neenyah Ostrom (Print Edition)

What Really Killed Gilda Radner? Frontline Reports on the Chronic Fatigue Syndrome Epidemic by Neenyah Ostrom (Print Edition)

50 Things You Should Know About the Chronic Fatigue Syndrome Epidemic by Neenyah Ostrom (Print Edition)


The Closing Argument by Charles Ortleb (Available on Kindle and in a Print Edition. Free for Kindle owners with Amazon Prime.)

The Virus Within by Nicholas Regush (Print Edition)

Introductory Lectures (Be sure to take notes.)

Did John Beldekas discover HHV-6 Before Gallo?

HHV-6 and the Immune System 

HHV-6 and Endogenous Retroviruses

HHV-6 and Natural Killer Cells 

HHV-6 and T Cells 

HHV-6 and B Cells

HHV-6 and Monocytes/Macrophages

HHV-6 and Dendritic Cells

HHV-6 and Mitochondria

HHV-6 and Apoptosis 

HHV-6 can be a Hemorrhagic Virus 

HHV-6 and Cancer

HHV-6 and the Brain

HHV-6 and Autoimmunity

HHV-6 and AIDS

HHV-6 and Chronic Fatigue Syndrome

HHV-6 and Autism

HHV-6 and Multiple Sclerosis
  
HHV-6 and Epilepsy

HHV-6 and the Brain

HHV-6 and the Heart

HHV-6 and the Immune System

HHV-6 and the Lymph Nodes

HHV-6 and the Lungs
  
HHV-6 and the Thyroid 

HHV-6 and the Skin 

HHV-6 and Chimerism

Epidemiology of HHV-6 

Robert Gallo on HHV-6 as 50 Shades of AIDS

Konnie Knox on HHV-6 

Dharam Ablashi on HHV-6

HHV-6 and CFS  Cartoons 



Coming soon:

The Controversial Discovery of HHV-6
The Nature of the Virus
The HHV-6 Paradox
HHV-6 and the Endocrine System
HHV-6’s Interaction with CMV
HHV-6 and the Gastrointestinal Tract
The Genetics of HHV-6
HHV-6 and the Thyroid
HHV-6 and Inflammation
HHV-6 and the Eyes
HHV-6 and Kaposi’s sarcoma
HHV-6 and Cancer (HHV-6 as an oncogenic virus)
HHV-6 and Cervical Epithelial Cells
HHV-6 and Alzheimer’s Disease
HHV-6 and Graft Versus Host Disease
HHV-6 and Diabetes
HHV-6 and Miscarriages
HHV-6 and Meningitis
Treatments for HHV-6
Drug Resistance and HHV-6
Animal Models for HHV-6
The Leading HHV-6 Researchers

See all the cartoons on this site!

Click here to see all our cartoons:
http://hhv6.blogspot.com/search?q=cartoons

Thyroiditis: One of HHV-6's 50 Shades of Non-HIV AIDS

Drug reaction with eosinophilia and systemic symptoms and thyroiditis: human herpesvirus-6, the possible common link.

 http://www.mecfsforums.com/index.php/topic,21877.0.html

 

Anti-thyroid antibodies strongly linked to fibromyalgia, pain in patients with RA

 http://www.healio.com/rheumatology/fibromyalgia/news/online/%7Becedc66c-ec7c-4bd9-b165-b8f62432cf8a%7D/anti-thyroid-antibodies-strongly-linked-to-fibromyalgia-pain-in-patients-with-ra

Monday, January 19, 2015

Do pets get Non-HIV AIDS from their owners and vice versa?

Dr. Thomas Glass on Chronic Fatigue Syndrome and pets. Did he inadvertently establish the first animal model for Chronic Fatigue Syndrome and HHV-6? If the agent responsible for the illness in both people and their pets is HHV-6, we may have definitive proof that HHV-6 is the cause of Chronic Fatigue Syndrome. And that could be just the beginning of the HHV-6 story.

Glass, R. 2000. Abnormal signs found in animals of myalgic encephalomyelitis/chronic fatigue syndrome patients: A look at 463 animals. Journal of Chronic Fatigue Syndrome 6:73-81.

Glass, R.T. 2000. The human/animal interaction in myalgic encephalomyelitis/chronic fatigue syndrome: A look at 127 patients. Journal of Chronic Fatigue Syndrome 6:65-72.

Glass, R.T. 1998. Autopsy findings of chronically ill animals of patients with chronic fatigue and immune dysfunction syndrome and autopsy findings of acutely ill animals who receive the agent which produces chronic fatigue and immune dysfunction syndrome. Medical Professional/Persons with CFIDS News 3:1-4.

Glass, R.T. 1998. The human/animal interaction of chronic fatigue and immune dysfunction syndrome: A look at 127 patients and their 463 animals. Medical Professional/Persons with CFIDS News 3:2-4, 15.

Martin, W.J. and Glass, R.T. 1995. Acute encephalopathy induced in cats with a stealth virus isolated from a patient with chronic fatigue syndrome. Pathobiology 63:115-118.

Gallo on HHV-6 and AIDS

Is HHV-6 the real AIDS Virus? Is it also the cause of Non-HIV AIDS???


The Name War

myalgic encephalomyelitis, aids, cfs, chronic fatigue syndroem, julian lake, gay, epidemiology

Gut-Brain Dysfunction: One of HHV-6's 50 Shades of Non-HIV AIDS

Autonomic nervous system dysregulation in irritable bowel syndrome

http://onlinelibrary.wiley.com/doi/10.1111/nmo.12512/abstract

Conclusions & Inferences

IBS subjects display a significant reduction in α index, an established marker of cardiac baroreflex. ANS dysfunction appears to be involved in the pathophysiology of IBS and its assessment may open new perspectives for clinical management of patients suffering from IBS.

Immunomodulation and immunosuppression by human herpesvirus 6A and 6B

http://www.futuremedicine.com/doi/abs/10.2217/fvl.13.7

Lorenzo Dagna Joshua C Pritchett & Paolo Lusso

Vol. 8, No. 3, Pages 273-287 , DOI 10.2217/fvl.13.7
(doi:10.2217/fvl.13.7) 
 
"Like other members of the Herpesviridae family, human herpesvirus (HHV)-6A and HHV-6B have developed a wide variety of strategies to modulate or suppress host immune responses and, thereby, facilitate their own spread and persistence in vivo. Long considered two variants of the same virus, HHV-6A and HHV-6B have recently been reclassified as distinct viral species, although the established nomenclature has been maintained. In this review, we summarize the distinctive profiles of interaction of these two viruses with the human immune system. Both HHV-6A and HHV-6B display a tropism for CD4+ T lymphocytes, but they can also infect, in a productive or nonproductive fashion, other cells of the immune system. However, there are important differences regarding the ability of each virus to infect cytotoxic effector cells, as HHV-6A has been shown to productively infect several of these cells, whereas HHV-6B infects them inefficiently at best. In addition to direct cytopathic effects, both HHV-6A and HHV-6B can interfere with immunologic functions to varying degrees via cytokine modulation, including blockade of IL-12 production by professional antigen-presenting cells, modulation of cell-surface molecules essential for T-cell activation, and expression of viral chemokines and chemokine receptors. Some of these effects are related to signaling through and downregulation of the viral receptor, CD46, a key molecule linking innate and adaptive immune responses. Increasing attention has recently been focused on the importance of viral interactions with dendritic cells, which may serve both as targets of virus-mediated immunosuppression and as vehicles for viral transfer to CD4+ T cells. Our deepening knowledge of the mechanisms developed by HHV-6A and HHV-6B to evade immunologic control may lead to new strategies for the prevention and treatment of the diseases associated with these viruses. Moreover, elucidation of these viral mechanisms may uncover new avenues to therapeutically manipulate or modulate the immune system in immunologically mediated human diseases."

Cockamamie study on HHV-6 and AIDS

http://www.ncbi.nlm.nih.gov/pubmed/24555113

Posts on HHV-6 and AIDS

Thursday, January 15, 2015

OMG!

Herpesvirus in the oral cavity of children with leukaemia and its impact on the oral bacterial community profile

http://jcp.bmj.com/content/early/2015/01/13/jclinpath-2014-202668.short?g=w_jcp_ahead_tab

"Results All the children with leukaemia were positive for at least one type of herpesvirus, compared with healthy participants (33.3%; p<0.000). Human cytomegalovirus (HCMV; 46.7%), human herpesvirus-7 (HHV-7; 20%) and HHV-8 (77.3%) were in higher prevalence in the LG (p≤0.01). Children with leukaemia had positive associations with the presence of HCMV, HHV-7 and HHV-8 in the oral cavity when under chemotherapy (p<0.05). There was a qualitative (means of DGGE bands) and quantitative (means of 16S rRNA gene abundance) difference in relation to the bacterial community between the two groups (p<0.05).
Conclusions Based on the results, the prevalence of herpesviruses and the qualitative bacterial profiles was higher in children with leukaemia and HCMV, HHV-7 and HHV-8 were related to the use of chemotherapy. Moreover, HHV-6 was correlated with an increased bacterial community profile in patients with leukaemia (p<0.05). More attention should be paid to the oral health of these individuals, mainly those under chemotherapy, in order to prevent infections by opportunistic pathogens"

Mikovits: "What honest scientist would would ever study the link between retrovirus, vaccines and any disease after my mug shot appears in arguably one of the best scientific journals in the world?"

http://prn.fm/tag/judy-mikovits/

CFS researcher says she was infected with virus linked to Chronic Fatigue Syndrome during her research

http://prn.fm/tag/judy-mikovits/

Interview with the woman who called Chronic Fatigue Syndrome non-HIV AIDS

A shocking interview with Judy Mikovits:
http://prn.fm/tag/judy-mikovits/

More posts related to scientist Judy Mikovits 

Karen Lambert on CFS as non-HIV AIDS

Cervical Cancer: One of HHV-6's 50 Shades of Non-HIV AIDS

http://www.ncbi.nlm.nih.gov/pubmed/9077427

HHV-6 and the microbiome.

http://www.ncbi.nlm.nih.gov/pubmed/23611298

Breaking News from Atlanta

cartoon, cdc, cfs, atlanta, conference, Chronic Fatigue Syndrome, Julian Lake

HHV-6 dormancy: truth or bullshit?

Human Herpesviruses HHV-6A, HHV-6B & HHV-7: Diagnosis and Clinical Management. 3rd ed. 

http://cid.oxfordjournals.org/content/60/3/496.extract

Familial Glioma: One of HHV-6's 50 Shades of Non-HIV AIDS

http://www.ncbi.nlm.nih.gov/pubmed/22591997

Monday, January 12, 2015

CFS and HHV-6 books available on Kindle Unlimited

These two unique books about CFS and HHV-6 are available on Kindle Unlimited.

The Chronic Fatigue Syndrome Follies: Cartoons about an epidemic of lies. [Kindle Edition]

A collection of cartoons about the cover-up of the Chronic Fatigue Syndrome epidemic. Anyone who knows the whole sorry story about the Chronic Fatigue Syndrome epidemic will tell you that it is one of the great tragedies in world history. A syndrome with so many similarities to AIDS that it has been called "AIDS Minor," CFS has been swept under the rug for three decades while millions of people have seen every aspect of their lives ruined. Patients have trouble deciding whether the government scientists in charge of researching it are liars or just plain stupid and incompetent. In other word,s CFS is the perfect subject for the pen of a caustic satirist. Cartoonist Julian Lake has used his sharp wit to capture the absurdities of a vast epidemic that has been hidden in plain sight by medical authorities who have put the whole world at risk. But sufferers of CFS are no different from the victims of any other political injustice. They may have have been lied to and may have had to live with compromised immune systems, but they haven't lost their sense of humor. There are times in the darkest chapters of history when one just has to laugh. This collection of often hilarious, uncompromising cartoons will garner smiles of recognition from anyone who has any familiarity with the crazy, ugly story of Chronic Fatigue Syndrome and the outrageous attempts to cover it up. The cartoons in this collection are like drones that never miss their targets.

The Closing Argument

"Ortleb's courageous and tireless investigative journalism (starting with his work as publisher @ NY Native Newspaper back in the 1980s') is second-to-none. While I generally prefer reading non-fiction over fiction, this novel leaves you jaw-dropped. It is clear that Ortleb is scientifically, well-researched in the field of CFS/AIDS, and understands the pandemic from its inception. Once again, Ortleb pushes the envelope with The Closing Argument --- moving humanity forward"

Low Natural Killer Cells: One of HHV-6's 50 Shades of Non-HIV AIDS



Posts on HHV-6 and Natural Killer Cells

Low Natural Killer (NK) Activity Observed Across the Chronic Fatigue Syndrome (CFS) Disease Spectrum

http://www.globenewswire.com/news-release/2015/01/12/696686/10115028/en/Low-Natural-Killer-NK-Activity-Observed-Across-the-Chronic-Fatigue-Syndrome-CFS-Disease-Spectrum.html
| Source: Hemispherx Biopharma, Inc.
PHILADELPHIA, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has conducted new in vitro studies of natural killer (NK) cells obtained from CFS patients in conjunction with a comprehensive review of the medical literature to determine the relative incidence of NK cell functional deficiencies in CFS disease. This review indicates that low NK cell cytotoxicity (NKCC) has been consistently reported in CFS patients compared to normal controls. In the new laboratory studies, Ampligen® (rintatolimod), an experimental therapeutic, was found to increase in vitro NK activity utilizing cells from CFS patient donors. The authors of the new report are all affiliated with Hemispherx.
NK cells are an important component of the innate immune response and may play an important role as a surveillance mechanism against viruses, other microbial pathogens, and tumor cells (Herberman, et al. Science 1981; 214:24-30). CFS is a debilitating disorder, characterized by disabling fatigue, flu-like symptoms, recurrent infections, and an apparent increased incidence of certain cancers, including lymphomas and brain tumors (Levine, et al. Ann Epidemiol 1998;8:245-249). The vast majority (88%) of published studies (15 of 17) evaluating NKCC in patients meeting Centers for Disease Control (CDC) disease criteria for CFS concluded that CFS is associated with a reduction in NKCC compared to healthy controls. Two of the studies that did not find a difference in NKCC between CFS patients and normal controls appear to contain design flaws, which may have influenced results, for example, including the exclusion of CFS patients sick for 10 years or longer. Notably, studies at the University of Miami (176 CFS patients) found a range of 2 to 25 years from onset of CFS symptoms with an average of 10 years (Fletcher, et al. PLoS One 2010; 5(5):e10817).
The medical literature indicates that the mean percent decrease in NKCC for the CFS population as defined using the CDC 1988 diagnostic criteria is significantly greater than that for the CFS patients defined by the CDC 1994 diagnostic criteria (the CDC 1988 criteria require more symptomatology to meet the requirements for a CFS diagnosis). Multiple published studies presented data, which support a relationship between a lower NKCC and a higher level of CFS symptom severity.
Ampligen® (rintatolimod), an experimental therapeutic, increased mean NK cell activity in vitro over 100% in the fifteen (15) CFS patients who donated NK cells. The mean age of the subject population was 48 years and two-thirds of the subjects were female. The observed NKCC increase was achieved with concentrations of Ampligen® achievable with a standard clinical treatment regimen of 400 mg given twice weekly. More than 100,000 doses have been given clinically, principally to CFS patients.
Historically, Hemispherx's double-blind, placebo-controlled and open-label clinical trials in CFS have emphasized quantitative measures of increased physical performance. For example, in a Phase III trial comparing twice weekly IV Ampligen® vs. placebo conducted in 234 subjects with long-standing debilitating CFS, the primary endpoint was intra-patient change from baseline at week 40 in exercise tolerance (ET). Subjects receiving Ampligen® for 40 weeks improved intra-patient placebo adjusted ET 21.3% from baseline in an intent-to-treat analysis. Correction for subjects with reduced dosing compliance increased placebo adjusted improvement to 28% (p=0.022) (Strayer, et al. PLoS ONE 7(3):e31334. doi:10.1371/journal.pone.0031334). The improvement observed represented approximately twice the minimum considered medically significant by regulatory agencies.
An FDA Advisory Committee, convened in December 2012, when asked "Is the safety profile of Ampligen® adequate for approval for the treatment of CFS?", the "Yes" vote was 8, and the "No" vote was 5. When asked has the application "provided sufficient efficacy and safety data to support marketing of Ampligen® for the treatment of chronic fatigue syndrome?", the "Yes" vote was 5 and the "No" vote was 8. Thereafter, the Agency declined to approve the marketing application. Subsequently, the Company has been in dialogue with the Agency as well as selected regulatory authorities worldwide regarding potential paths forward to advance the experimental product for potential treatment of severe CFS.
The evidence that severity of CFS is associated with progressive derangement of immune surveillance mediated by NK cells may afford a new path to identify opportunities for CFS therapeutic intervention. While NK studies were not systematically performed in the earlier well-controlled clinical study cited in the PLoS One peer-reviewed publication, improvements in vitality score, Activities of Daily Living score, and reduction in concomitant medications usage were observed. Quality-of-life improvements may be sequelae of improved immunosurveillance.
About Ampligen®
Ampligen®, an experimental therapeutic, is a new class of specifically-configured ribonucleic acid (RNA) compounds targeted as potential treatment of diseases with immunologic defects and/or viral causation.
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders especially life-threatening viruses. Hemispherx's flagship products include Alferon® N Injection® and the experimental therapeutics Ampligen® and Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases including cancers. Because both Ampligen® and Alferon® LDO are experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon® N Injection®), approved for sale in the U.S. and Argentina. The FDA approval of Alferon® N Injection® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. The Company's Alferon N Injection® approval in Argentina includes the use of Alferon N Injection® (under the brand name "Naturaferon") for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.
- See more at: http://www.globenewswire.com/news-release/2015/01/12/696686/10115028/en/Low-Natural-Killer-NK-Activity-Observed-Across-the-Chronic-Fatigue-Syndrome-CFS-Disease-Spectrum.html#sthash.ftYoq8CZ.dpuf
| Source: Hemispherx Biopharma, Inc.
PHILADELPHIA, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has conducted new in vitro studies of natural killer (NK) cells obtained from CFS patients in conjunction with a comprehensive review of the medical literature to determine the relative incidence of NK cell functional deficiencies in CFS disease. This review indicates that low NK cell cytotoxicity (NKCC) has been consistently reported in CFS patients compared to normal controls. In the new laboratory studies, Ampligen® (rintatolimod), an experimental therapeutic, was found to increase in vitro NK activity utilizing cells from CFS patient donors. The authors of the new report are all affiliated with Hemispherx.
NK cells are an important component of the innate immune response and may play an important role as a surveillance mechanism against viruses, other microbial pathogens, and tumor cells (Herberman, et al. Science 1981; 214:24-30). CFS is a debilitating disorder, characterized by disabling fatigue, flu-like symptoms, recurrent infections, and an apparent increased incidence of certain cancers, including lymphomas and brain tumors (Levine, et al. Ann Epidemiol 1998;8:245-249). The vast majority (88%) of published studies (15 of 17) evaluating NKCC in patients meeting Centers for Disease Control (CDC) disease criteria for CFS concluded that CFS is associated with a reduction in NKCC compared to healthy controls. Two of the studies that did not find a difference in NKCC between CFS patients and normal controls appear to contain design flaws, which may have influenced results, for example, including the exclusion of CFS patients sick for 10 years or longer. Notably, studies at the University of Miami (176 CFS patients) found a range of 2 to 25 years from onset of CFS symptoms with an average of 10 years (Fletcher, et al. PLoS One 2010; 5(5):e10817).
The medical literature indicates that the mean percent decrease in NKCC for the CFS population as defined using the CDC 1988 diagnostic criteria is significantly greater than that for the CFS patients defined by the CDC 1994 diagnostic criteria (the CDC 1988 criteria require more symptomatology to meet the requirements for a CFS diagnosis). Multiple published studies presented data, which support a relationship between a lower NKCC and a higher level of CFS symptom severity.
Ampligen® (rintatolimod), an experimental therapeutic, increased mean NK cell activity in vitro over 100% in the fifteen (15) CFS patients who donated NK cells. The mean age of the subject population was 48 years and two-thirds of the subjects were female. The observed NKCC increase was achieved with concentrations of Ampligen® achievable with a standard clinical treatment regimen of 400 mg given twice weekly. More than 100,000 doses have been given clinically, principally to CFS patients.
Historically, Hemispherx's double-blind, placebo-controlled and open-label clinical trials in CFS have emphasized quantitative measures of increased physical performance. For example, in a Phase III trial comparing twice weekly IV Ampligen® vs. placebo conducted in 234 subjects with long-standing debilitating CFS, the primary endpoint was intra-patient change from baseline at week 40 in exercise tolerance (ET). Subjects receiving Ampligen® for 40 weeks improved intra-patient placebo adjusted ET 21.3% from baseline in an intent-to-treat analysis. Correction for subjects with reduced dosing compliance increased placebo adjusted improvement to 28% (p=0.022) (Strayer, et al. PLoS ONE 7(3):e31334. doi:10.1371/journal.pone.0031334). The improvement observed represented approximately twice the minimum considered medically significant by regulatory agencies.
An FDA Advisory Committee, convened in December 2012, when asked "Is the safety profile of Ampligen® adequate for approval for the treatment of CFS?", the "Yes" vote was 8, and the "No" vote was 5. When asked has the application "provided sufficient efficacy and safety data to support marketing of Ampligen® for the treatment of chronic fatigue syndrome?", the "Yes" vote was 5 and the "No" vote was 8. Thereafter, the Agency declined to approve the marketing application. Subsequently, the Company has been in dialogue with the Agency as well as selected regulatory authorities worldwide regarding potential paths forward to advance the experimental product for potential treatment of severe CFS.
The evidence that severity of CFS is associated with progressive derangement of immune surveillance mediated by NK cells may afford a new path to identify opportunities for CFS therapeutic intervention. While NK studies were not systematically performed in the earlier well-controlled clinical study cited in the PLoS One peer-reviewed publication, improvements in vitality score, Activities of Daily Living score, and reduction in concomitant medications usage were observed. Quality-of-life improvements may be sequelae of improved immunosurveillance.
About Ampligen®
Ampligen®, an experimental therapeutic, is a new class of specifically-configured ribonucleic acid (RNA) compounds targeted as potential treatment of diseases with immunologic defects and/or viral causation.
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders especially life-threatening viruses. Hemispherx's flagship products include Alferon® N Injection® and the experimental therapeutics Ampligen® and Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases including cancers. Because both Ampligen® and Alferon® LDO are experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon® N Injection®), approved for sale in the U.S. and Argentina. The FDA approval of Alferon® N Injection® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. The Company's Alferon N Injection® approval in Argentina includes the use of Alferon N Injection® (under the brand name "Naturaferon") for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.
- See more at: http://www.globenewswire.com/news-release/2015/01/12/696686/10115028/en/Low-Natural-Killer-NK-Activity-Observed-Across-the-Chronic-Fatigue-Syndrome-CFS-Disease-Spectrum.html#sthash.ftYoq8CZ.dpuf
| Source: Hemispherx Biopharma, Inc.
PHILADELPHIA, Jan. 12, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), reported today that it has conducted new in vitro studies of natural killer (NK) cells obtained from CFS patients in conjunction with a comprehensive review of the medical literature to determine the relative incidence of NK cell functional deficiencies in CFS disease. This review indicates that low NK cell cytotoxicity (NKCC) has been consistently reported in CFS patients compared to normal controls. In the new laboratory studies, Ampligen® (rintatolimod), an experimental therapeutic, was found to increase in vitro NK activity utilizing cells from CFS patient donors. The authors of the new report are all affiliated with Hemispherx.
NK cells are an important component of the innate immune response and may play an important role as a surveillance mechanism against viruses, other microbial pathogens, and tumor cells (Herberman, et al. Science 1981; 214:24-30). CFS is a debilitating disorder, characterized by disabling fatigue, flu-like symptoms, recurrent infections, and an apparent increased incidence of certain cancers, including lymphomas and brain tumors (Levine, et al. Ann Epidemiol 1998;8:245-249). The vast majority (88%) of published studies (15 of 17) evaluating NKCC in patients meeting Centers for Disease Control (CDC) disease criteria for CFS concluded that CFS is associated with a reduction in NKCC compared to healthy controls. Two of the studies that did not find a difference in NKCC between CFS patients and normal controls appear to contain design flaws, which may have influenced results, for example, including the exclusion of CFS patients sick for 10 years or longer. Notably, studies at the University of Miami (176 CFS patients) found a range of 2 to 25 years from onset of CFS symptoms with an average of 10 years (Fletcher, et al. PLoS One 2010; 5(5):e10817).
The medical literature indicates that the mean percent decrease in NKCC for the CFS population as defined using the CDC 1988 diagnostic criteria is significantly greater than that for the CFS patients defined by the CDC 1994 diagnostic criteria (the CDC 1988 criteria require more symptomatology to meet the requirements for a CFS diagnosis). Multiple published studies presented data, which support a relationship between a lower NKCC and a higher level of CFS symptom severity.
Ampligen® (rintatolimod), an experimental therapeutic, increased mean NK cell activity in vitro over 100% in the fifteen (15) CFS patients who donated NK cells. The mean age of the subject population was 48 years and two-thirds of the subjects were female. The observed NKCC increase was achieved with concentrations of Ampligen® achievable with a standard clinical treatment regimen of 400 mg given twice weekly. More than 100,000 doses have been given clinically, principally to CFS patients.
Historically, Hemispherx's double-blind, placebo-controlled and open-label clinical trials in CFS have emphasized quantitative measures of increased physical performance. For example, in a Phase III trial comparing twice weekly IV Ampligen® vs. placebo conducted in 234 subjects with long-standing debilitating CFS, the primary endpoint was intra-patient change from baseline at week 40 in exercise tolerance (ET). Subjects receiving Ampligen® for 40 weeks improved intra-patient placebo adjusted ET 21.3% from baseline in an intent-to-treat analysis. Correction for subjects with reduced dosing compliance increased placebo adjusted improvement to 28% (p=0.022) (Strayer, et al. PLoS ONE 7(3):e31334. doi:10.1371/journal.pone.0031334). The improvement observed represented approximately twice the minimum considered medically significant by regulatory agencies.
An FDA Advisory Committee, convened in December 2012, when asked "Is the safety profile of Ampligen® adequate for approval for the treatment of CFS?", the "Yes" vote was 8, and the "No" vote was 5. When asked has the application "provided sufficient efficacy and safety data to support marketing of Ampligen® for the treatment of chronic fatigue syndrome?", the "Yes" vote was 5 and the "No" vote was 8. Thereafter, the Agency declined to approve the marketing application. Subsequently, the Company has been in dialogue with the Agency as well as selected regulatory authorities worldwide regarding potential paths forward to advance the experimental product for potential treatment of severe CFS.
The evidence that severity of CFS is associated with progressive derangement of immune surveillance mediated by NK cells may afford a new path to identify opportunities for CFS therapeutic intervention. While NK studies were not systematically performed in the earlier well-controlled clinical study cited in the PLoS One peer-reviewed publication, improvements in vitality score, Activities of Daily Living score, and reduction in concomitant medications usage were observed. Quality-of-life improvements may be sequelae of improved immunosurveillance.
About Ampligen®
Ampligen®, an experimental therapeutic, is a new class of specifically-configured ribonucleic acid (RNA) compounds targeted as potential treatment of diseases with immunologic defects and/or viral causation.
About Hemispherx Biopharma
Hemispherx Biopharma, Inc. is an advanced specialty pharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of seriously debilitating disorders especially life-threatening viruses. Hemispherx's flagship products include Alferon® N Injection® and the experimental therapeutics Ampligen® and Alferon® LDO. Ampligen® is an experimental RNA nucleic acid being developed for globally important debilitating diseases and disorders of the immune system, including Chronic Fatigue Syndrome. Hemispherx's platform technology includes components for potential treatment of various severely debilitating and life threatening diseases including cancers. Because both Ampligen® and Alferon® LDO are experimental in nature, they are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials. Hemispherx has patents comprising its core intellectual property estate and a fully commercialized product (Alferon® N Injection®), approved for sale in the U.S. and Argentina. The FDA approval of Alferon® N Injection® is limited to the treatment of refractory or recurrent external genital warts in patients 18 years of age or older. The Company's Alferon N Injection® approval in Argentina includes the use of Alferon N Injection® (under the brand name "Naturaferon") for use in any patients who fail, or become intolerant to recombinant interferon, including patients with chronic active hepatitis C infection. The Company wholly owns and exclusively operates a GMP certified manufacturing facility in the United States for commercial products. For more information please visit www.hemispherx.net.
- See more at: http://www.globenewswire.com/news-release/2015/01/12/696686/10115028/en/Low-Natural-Killer-NK-Activity-Observed-Across-the-Chronic-Fatigue-Syndrome-CFS-Disease-Spectrum.html#sthash.ftYoq8CZ.dpuf

Robert Gallo on HHV-6 as 50 Shades of non-HIV AIDS

Gallo may inadvertently have been the first person to establish that HHV-6 = 50 Shades of AIDS.


Posts on Robert Gallo and HHV-6

Inflammatory Pathology: One of HHV-6's 50 Shades of Non-HIV AIDS

http://www.ncbi.nlm.nih.gov/pubmed/?term=tweedy+hhv-6

Encephalitis: One of HHV-6's 50 Shades of Non-HIV AIDS

http://www.ncbi.nlm.nih.gov/pubmed/?term=hhv-6+status+epilpeticus+immunocompentent

Skin Diseases: Some of HHV-6's Shades of Non-HIV AIDS

http://www.nature.com/jidsp/journal/v6/n3/full/5640056a.html

Thursday, January 08, 2015

Should Chronic Fatigue Syndrome be renamed "50 Shades of Non-HIV AIDS?

http://www.medscape.com/viewarticle/837577

Komaroff on Chronic Fatigue Synrome

"At a Stanford meeting held earlier this year, Dr Komaroff pointed out that many of the infectious agents that have been linked to ME/CFS—including Epstein-Barr virus,[17] HHV-6,[18] Coxiella burnetii (aka "Q fever"),[19] Ross River virus in Australia,[20] and various enteroviruses[21]—are ones that can't be fully eradicated by the immune system even in healthy people and/or are capable of infecting the central nervous system. This suggests the possibility that some ME/CFS patients may have a chronic, low-level encephalitis, he postulated."

Source:
 Chronic Fatigue Syndrome: Wrong Name, Real Illness by Miriam E. Tucker
 http://www.medscape.com/viewarticle/837577_4 

Hillary Johnson, the author of "Osler's Web," recommends Julian Lakes's cartoon book on Chronic Fatigue Syndrome

https://twitter.com/oslersweb/status/552982517511630850

Wednesday, January 07, 2015

Breaking News: Is America's Centers for Disease Control ever going to admit African Swine Fever Virus can infect humans?

A new paper on African Swine Fever Virus from the CDC's Emerging Infectious Diseases, a peer reviewed, open access journal published monthly by the Centers for Disease Control and Prevention (CDC)

http://wwwnc.cdc.gov/eid/article/21/2/14-0649_article

For more info on ASFV as a human infection:

http://humanasfv.blogspot.com/

What every Journalist should know about African Swine Fever Virus:
 


Russian Scientist: ASF could become a human health risk


"The African swine fever (ASF) virus, may in the future become dangerous for humans, according to the head of the Russian Epidemiology Service, Chief State Sanitary Doctor Gennady Onishchenko, at the press-conference in St. Petersburg. According to him almost all viruses from time to time go through mutation processes which can give them some additional functions."

 http://www.pigprogress.net/Health-Diseases/Outbreaks/2013/7/ASF-could-become-a-human-health-risk-1308047W/

 

 



Background on African Swine Fever Virus as a human pathogen:

"African Swine fever is an endemic disease in sub-Saharan Africa and many other parts of the developing world. It is caused by the African Swine virus that primarily replicates in macrophages and monocytes leading to the impairment of the structure and function of the immune system of the infected organisms. Until now the African Swine epidemic continues to spread despite all efforts to contain it. Thus, there is an objective need for effective, safe and affordable preventive and therapeutic approaches, in particular for effective vaccines, to control and eventually eradicate this disease. Since the characteristic feature of the African Swine virus is to impair the immune system and to cause immune deficiencies in its hosts the development of vaccines and other therapeutic approaches against the African Swine virus has implications for other immune deficiencies or diseases. Several other viruses are also known to cause immunodeficiency-like syndromes in humans, including cytomegalovirus, Epstein Barr Virus and others. Moreover, a series of cases of so-called "idiopathic" immunodeficiencies have been documented that display CD4+T-lymphocytopenia with opportunistic infections, but show no evidence of HIV infection. Since antibodies for the African Swine virus have been detected in humans, the possibility of human infection with the African Swine virus exists and may thus far have escaped any systematic screening. Thus, any preventive and therapeutic approach to African Swine fever can have far-reaching implications to control immune deficiency conditions in humans."http://www.faqs.org/patents/app/20080207875
Detection of Novel Sequences Related to African Swine Fever Virus in Human Serum and Sewage.

Loh J, Zhao G, Presti RM, Holtz LR, Finkbeiner SR, Droit L, Villasana Z, Todd C, Pipas JM, Calgua B, Girones R, Wang D, Virgin HW.

Departments of Pathology & Immunology and Molecular Microbiology, Department of Medicine and Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri; Department of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Microbiology, Faculty of Biology, University of Barcelona, Barcelona, Spain.

"The family Asfarviridae contains only a single virus species, African swine fever virus (ASFV). ASFV is a viral agent with significant economic impact due to its devastating effects on populations of domesticated pigs during outbreaks, but has not been reported to infect humans. We report here the discovery of novel viral sequences in human serum and sewage which are clearly related to the Asfarvirus family, but highly divergent from ASFV. Detection of these sequences suggests that greater genetic diversity may exist among Asfarviruses than previously thought, and raises the possibility that human infection by Asfarviruses may occur."
http://www.ncbi.nlm.nih.gov/pubmed/19812170?dopt=Abstract

African Swine Fever Virus (Asfarviridae) sequences found in people with febrile illnesses

Abstract
Virus Identification in Unknown Tropical Febrile Illness Cases Using Deep Sequencing
Dengue virus is an emerging infectious agent that infects an estimated 50–100 million people annually worldwide, yet current diagnostic practices cannot detect an etiologic pathogen in ∼40% of dengue-like illnesses. Metagenomic approaches to pathogen detection, such as viral microarrays and deep sequencing, are promising tools to address emerging and non-diagnosable disease challenges. In this study, we used the Virochip microarray and deep sequencing to characterize the spectrum of viruses present in human sera from 123 Nicaraguan patients presenting with dengue-like symptoms but testing negative for dengue virus. We utilized a barcoding strategy to simultaneously deep sequence multiple serum specimens, generating on average over 1 million reads per sample. We then implemented a stepwise bioinformatic filtering pipeline to remove the majority of human and low-quality sequences to improve the speed and accuracy of subsequent unbiased database searches. By deep sequencing, we were able to detect virus sequence in 37% (45/123) of previously negative cases. These included 13 cases with Human Herpesvirus 6 sequences. Other samples contained sequences with similarity to sequences from viruses in the Herpesviridae, Flaviviridae, Circoviridae, Anelloviridae, Asfarviridae, and Parvoviridae families. In some cases, the putative viral sequences were virtually identical to known viruses, and in others they diverged, suggesting that they may derive from novel viruses. These results demonstrate the utility of unbiased metagenomic approaches in the detection of known and divergent viruses in the study of tropical febrile illness.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3274504/

Detection of African swine fever virus-like sequences in ponds in the Mississippi Delta through metagenomic sequencing

" . .. further study is needed to characterize their potential risks to both public health and agricultural development."

http://link.springer.com/article/10.1007%2Fs11262-013-0878-2

ASF virus, adapted to grow in VERO cells, produces a strong cytopathic effect in human macrophages leading to cell destruction.

http://vir.sgmjournals.org/content/34/3/455.short

Tuesday, January 06, 2015

Monday, January 05, 2015

The best prevention

cartoon, cartoons, fauci, cfs, chronic fatigue synrome, pathway to prevention, fraud

African Swine Fever Virus (Asfarviridae) sequences and HHV-6 found in people with febrile illnesses


Abstract
Virus Identification in Unknown Tropical Febrile Illness Cases Using Deep Sequencing
Dengue virus is an emerging infectious agent that infects an estimated 50–100 million people annually worldwide, yet current diagnostic practices cannot detect an etiologic pathogen in ∼40% of dengue-like illnesses. Metagenomic approaches to pathogen detection, such as viral microarrays and deep sequencing, are promising tools to address emerging and non-diagnosable disease challenges. In this study, we used the Virochip microarray and deep sequencing to characterize the spectrum of viruses present in human sera from 123 Nicaraguan patients presenting with dengue-like symptoms but testing negative for dengue virus. We utilized a barcoding strategy to simultaneously deep sequence multiple serum specimens, generating on average over 1 million reads per sample. We then implemented a stepwise bioinformatic filtering pipeline to remove the majority of human and low-quality sequences to improve the speed and accuracy of subsequent unbiased database searches. By deep sequencing, we were able to detect virus sequence in 37% (45/123) of previously negative cases. These included 13 cases with Human Herpesvirus 6 sequences. Other samples contained sequences with similarity to sequences from viruses in the Herpesviridae, Flaviviridae, Circoviridae, Anelloviridae, Asfarviridae, and Parvoviridae families. In some cases, the putative viral sequences were virtually identical to known viruses, and in others they diverged, suggesting that they may derive from novel viruses. These results demonstrate the utility of unbiased metagenomic approaches in the detection of known and divergent viruses in the study of tropical febrile illness.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3274504/

Blog Archive

Popular Posts in the Last 30 Days

You can support us by listening to these songs by Charles Ortleb on Spotify.

cfs book scrib promo

Previous HHV-6 University Reports

ad for cfs book

Audible CFS book

Closing Argument Audible

African Swine Fever Novel Audible

Stonewall Audible